FOXO narrows Q2 loss to $0.49 EPS; capital structure streamlined, raises ~$260K in private placement

FOXO TECHNOLOGIES INC.

Basic EPS loss of $0.49 in Q2 2023 vs $3.84 loss a year ago; diluted loss $0.83 vs $6.01.
Adjusted EBITDA loss improved to $3.34M in Q2 from $8.82M in prior-year quarter; six-month loss $7.20M.
Completed two tender offers: 1.65M warrants exchanged for 7.96M shares; 4.32M shares issued to PIK note holders.
Raised ~$260K net proceeds from private placement of 5.625M shares of Class A common stock.
Launched Bioinformatics Services in July 2023; paused Longevity Report beta sales for further R&D.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FOXO TECHNOLOGIES INC. reported second quarter ended June 30, 2023 results: EPS $(0.49) and $(0.83) for the three and six months ended June 30, 2023, respectively from $(3.84) and $(6.01) for the thre.

Period: second quarter ended June 30, 2023
EPS: $(0.49) and $(0.83) for the three and six months ended June 30, 2023, respectively from $(3.84) and $(6.01) for the thre
Result: reported results

Exact text from the filing

FOXO Technologies Inc. (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today reported financial results for the second quarter ended June 30, 2023.

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

FOXO TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-065598

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.